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Background: Despite several studies about the effects of saffron supplementation on serum concentrations of
lipid and glucose profiles, no systematic study had summarized the findings. Therefore, we conduct current
study to systematically summarize findings from studies about the effect of saffron supplementation on serum
levels of glucose and lipid profiles and to do a meta-analysis, if possible.
Methods: A systematic literature search was conducted for clinical trials published in PubMed, SCOPUS,
EMBASE, Cochrane's Library and ISI Web of Science from the beginning to 22 February 2019. All randomized
clinical trials on the effect of saffron supplementation on serum concentrations of lipid and glucose profiles were
included.
Results: In overall, six studies were included in the current study. Pooled analysis of six studies for the effect of
saffron on serum TG, TC and FBG concentrations and of five studies for LDL and HDL, showed a significant
reduction in TG (WMD: -8.93 mg/dl; 95% CI: -16.49 to -1.37, P= 0.02) and TC levels (WMD: -5.72 mg/dl; 95%
CI: -11.10 to -0.34, P= 0.03), a significant increase in HDL levels (WMD: 2.7 mg/dl; 95% CI: 0.22 to 5.18,
P=0.03), and no significant effect on LDL (WMD: -2.30 mg/dl; 95% CI: -11.73 to 7.13, P= 0.63) and FBG
levels (WMD: -5.30 mg/dl; 95% CI: -14.20 to 3.60, P= 0.51).
Conclusion: We found a significant reduction in serum concentrations of TC and TG and a significant increase in
serum levels of HDL following supplementation with saffron. Saffron supplementation had no significant in-
fluence on serum FPG and LDL concentrations.
1. Introduction
Prevalence of chronic diseases is increasing worldwide.
Cardiovascular disease (CVDs) and diabetes mellitus are among the
most prevalent chronic diseases, which are known to be responsible for
million deaths annually. It is estimated that annual CVD mortality will
be increased to 25 million per year by 2020.1,2 On the other hand,
prevalence of diabetes has been increased worldwide. In 2017, about
451 million people had diabetes, and about 5 million deaths were oc-
curred due to diabetes.3 Therefore, control of complications of these
chronic conditions is a health priority.
Different classes of lipid-modulating and anti-diabetic agents are
used to modulate serum concentrations of glucose and lipids.4,5
However, several possible complications have been reported. There-
fore, recent efforts have been made to find herbal medicines for this
purpose. For instance, previous studies have shown significant effects of
ginger,6,7 cinnamon,8,9 turmeric,10 and ginseng 11 on modulation of
serum glucose and lipid profiles. In addition, additional single nu-
traceuticals and nutraceutical combinations such as berberine, phy-
tosterols, policosanol, soy products and red yeast rice have demon-
strated both lipid- and glucose-lowering effects.12,13 Saffron (Crocus
sativus L.) is a popular Iranian additive 14 which its beneficial effects on
several diseases have been found in previous studies. Although several
studies have investigated the effect of saffron supplementation on
serum glucose and lipids concentrations, findings are inconsistent.
Saffron supplementation has significantly reduced blood glucose and
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lipid profiles in some studies. However, some other studies failed to find
such the significant effects.14–19 Findings from a recent systematic re-
view and meta-analysis showed no significant effect of saffron supple-
mentation on lipid and glucose profiles.20 However, data from studies
that used each forms of saffron or its constituents were pooled in that
study. Due to the different influence of these interventions, findings
from that study are prone to bias.
Despite above mentioned controversies between available studies,
no earlier study has summarized findings from studies on the effects of
saffron alone on serum glucose and lipid profiles. Therefore, we con-
duct current study to systematically summarize findings from studies
about the effect of saffron supplementation on serum levels of glucose
and lipid profiles and to do a meta-analysis, if possible.
2. Materials and methods
This systematic review has been conducted according to the
PRISMA statement.21
2.1. Search strategy
Relevant papers published until february 2019 were searched
through the international scientific literature databases, including
PubMed, SCOPUS, EMBASE, Cochrane's Library and ISI Web of Science
without restriction of time or publication language. For this purpose,
we used the following keywords: (("Crocus sativus Linn "[Title/
Abstract] OR "Safranal "[Title/Abstract] OR "saffron "[Title/Abstract])
AND ("Diabetic"[Title/Abstract] OR "glucose"[Title/Abstract] OR
"fasting blood glucose"[Title/Abstract] OR "FBG"[Title/Abstract] OR
("hemoglobin A1c"[Title/Abstract] OR "HbA1c"[Title/Abstract] OR
"HOMA-IR"[Title/Abstract] OR "homeostatic model assessment"[Title/
Abstract] OR "Insulin"[Title/Abstract] OR "fasting blood sugar"[Title/
Abstract] OR "glycemia"[Title/Abstract] OR "glycaemia"[Title/
Abstract] OR "hyperglycaemia"[Title/Abstract] OR "FBS"[Title/
Abstract]) OR "triglyceride"[Title/Abstract] OR "Triacylglycerol"[Title/
Abstract] OR "cholesterol"[Title/Abstract] OR Lipoprotein"[Title/
Abstract] OR "very low density lipoprotein"[Title/Abstract] OR
"VLDL"[Title/Abstract] OR "low density lipoprotein"[Title/Abstract] OR
"LDL"[Title/Abstract] OR "LDL-C"[Title/Abstract] OR "high density
lipoprotein"[Title/Abstract] OR "HDL"[Title/Abstract] OR "HDL-
C"[Title/Abstract] OR "lipid"[Title/Abstract])). In addition, to avoid
missing of any other relevant publication, we also searched the re-
ference lists of relevant articles.
2.2. Inclusion criteria
All randomized clinical trials (RCTs) that investigated the effect of
saffron on blood glucose or lipid profile in adults were included.
2.3. Exclusion criteria
Studies with the following properties were excluded: 1) had ob-
servational design or were conducted in animal models; 2) conducted
on children (< 18 years); 3) did not perform randomized allocation; 4)
had no placebo-control group; 5) examined the effect of another in-
tervention along with saffron; 6) acute intervention, or 7) used an
specific type of saffron or its constituents.
2.4. Data extraction
Two researchers (NN, OA) independently extracted necessary in-
formation from the studies. Controversies were resolved by the third
researcher (AM). Following data were extracted: first author's name,
country, publication's year, study design, health condition of partici-
pants, study sample size in intervention and control groups, partici-
pants’ sex, participants’ mean age and body mass index, dosage of
saffron supplementation, duration of study, and means ± Standard
Deviation (SD) of biochemical profiles before and after intervention or
their changes throughout the intervention.
2.5. Quality assessment
Methodological quality of included studies was evaluated using the
Jadad scoring system. This scoring system contained five questions
about: 1) presence of randomization; 2) application of an appropriate
method for randomization; 3) presence of double-blinding; 4) applica-
tion of an appropriate method for double-blinding; and 5) providing
reasonable explanations for the withdrawals and dropouts. A score of 0
or 1 was given to each question. The scores were then summed up and a
total score of 0–5 was yielded.22 Studies with a total score of equal or
greater than 3 were considered as high-quality, while those with a total
score of less than 3 were considered as low-quality studies.22
2.6. Data synthesis and statistical analysis
Overall effect size was calculated using mean ± SD of changes in
serum concentrations of glucose and lipids within intervention and
control groups by the random-effect model,23 and was expressed as
weighted mean difference (WMD) and 95% CI. Evaluation of between-
study heterogeneity was performed using I-square (I2) and test Q test.
Subgroup analysis based on saffron dosage and duration of interven-
tion, baseline FBG, and blood lipids level, mean age, and study quality
was conducted to detect potential sources of heterogeneity.24 All other
statistics were converted to mean ± SD using proper formula. Median
and 95% confidence intervals were converted to mean and SD using the
method introduced by Hozo et al.25 Standard errors of mean (SEM)
were converted to SDs by S.D]S.E.M×√n (n is the number of partici-
pants in each group). If serum concentrations of a glucose or lipid
profile were reported in different units, we converted them into the
most frequently used unit. All analyses were done using the STATA
version 12 (Stata Corporation, College Station, TX, USA).
3. Results
Overall, 903 publications were found in the initial search through
Pubmed (n= 136), Scopus (n= 267), Web of science (n= 256),
Embase (n=222) and Cochrane (n=22). Overall, Overall, 903 pub-
lications were found in the initial search through Pubmed (n= 136),
Scopus (n=267), Web of science (n=256), Embase (n=222) and
Cochrane (n=22). Overall 14,15,17–19,26 were included in this meta-
analysis. The flow-diagram of study selection is presented in Fig. 1.
4. Study characteristics
The characteristics of included articles are summarized in the
Table 1. All papers were Randomized Clinical Trials (RCTs), published
between 2011 and 2018, which were done in Iran.14,15,17–19,26 The
duration of the intervention varied from 4 to 12 weeks. Saffron sup-
plements were used in dosages between 30 and 1000mg. A total of 147
participants in intervention group and 144 participants in control group
were enrolled.14,15,17–19,26 Participants of these studies had sexual
dysfunction,15 type 2 diabetes,14,26 schizophrenia,17 coronary artery
disease 18 and metabolic syndrome.19 One study was done exclusively
in men,17 while the other studies recruited both genders.14,15,18,19,26 As
measured by the Jadad scoring system, the quality of all included stu-
dies was moderate 26 or high.14,15,17–19
5. Meta-Analysis
Results of pooled fix or random-effect size (according to significant
or non-significant heterogeneity) analysis of six studies 14,15,17–19,26 for
TG, TC and FBG, and also five studies 14,17–19,26 for LDL and HDL
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showed significant decreasing effects of saffron supplementation on TG
(WMD: -8.93 mg/dl; 95% CI: -16.49 to -1.37, P=0.02) without no
significant heterogeneity shown within the studies (I2=42.8%,
P=0.120) and TC levels (WMD: -5.72 mg/dl; 95% CI: -11.10 to -0.34,
P=0.03) without significant heterogeneity shown within the studies
(I2= 42.8%, P=0.120), a significant effect on HDL level (WMD: 2.7
mg/dl; 95% CI: 0.22 to 5.18, P= 0.03) with significant heterogeneity
(I2= 69.8%, P= 0.01), However, supplementation with saffron did not
have a significant effects on LDL (WMD: -2.30 mg/dl; 95% CI: -11.73 to
7.13, P=0.63) and FBG levels (WMD: -5.30 mg/dl; 95% CI: -14.20 to
3.60, P= 0.51). The forest plots for the effects of saffron supple-
mentation on FBG, TG, TC, LDL and HDL are shown in Figs. 2–6 , re-
spectively. Subgroup analyses were performed to find probable ex-
planations for the between-study heterogeneities and to reach the best
conclusion:
6. Subgroup analyses
Subgroup analysis of the effect of saffron on serum concentrations of
FBG, LDL and HDL by the baseline values, trial duration, saffron dosage
and participants’ health condition was done due to significant hetero-
geneity (p < 0.05).
6.1. Subgroup analysis for the effects of saffron on FBG
After subgroup analysis heterogeneity was disappeared in studies
that, saffron dosages was>30mg (I2= 0.0%, P= 0.786). However,
saffron supplementation did not effect on serum concentrations of FBG
in all of the subgroups. (Table 2).
6.2. Subgroup analysis for the effects of saffron on LDL
Our subgroup analyses indicated no significant heterogeneity in
studies conducted on subjects without type 2 diabetes (I2= 2.5%,
P= 0.359) and studies with duration equal to 12 weeks (I2 47.8%,
P= 0.166). However, subgroup analysis shown that the effect of saf-
fron supplementation could reduce LDL concentration in non-type 2
diabetes subjects (WMD: -8.39mg/ dl; 95% CI: -15.19 to -1.59, P 0.016)
(Table 2).
6.3. Subgroup analysis for the effects of saffron on HDL
Subgroup analysis showed no evidence of between-study hetero-
geneity in studies that, saffron dosages was > 30mg (I2= 0.0%,
P= 0.750) and 30mg (I2= 0.0%, P= 0.686), and also, conducted on
subjects with HDL concentration higher than 50mg/dl (I2= 34.4%,
P= 0.218) and non-diabetes subjects (I2= 34.4%, P= 0.218). Also,
contrary to general analysis, the analysis of subgroups showed that,
saffron supplements have led to an increase in HDL concentration in
subjects with HDL level higher than 50mg/dl (WMD: 3.54mg/dl; 95%
CI: 0.87 to 6.22, P=0.009) and non-type 2 diabetes (WMD: 3.54mg/
dl; 95% CI: 0.87 to 6.22, P= 0.009), and also in studies that saffron
dosage equal to 30mg (WMD: 4.37mg/dl; 95% CI: 2.60 to 6.13,
P < 0.001) (Table 2).
Fig. 1. Flowchart of study selection for inclusion trials in the systematic review.
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7. Publication bias
Assessment of publication bias by the egger’s test indicated no
evidence of publication bias in the meta-analysis for the effects of saf-
fron supplementation on serum FBG (p= 0.361), TG (p= 0.547), TC
(p= 0.125), LDL (p=0.548), and HDL concentrations (p= 0.670).
8. Discussion
This meta-analysis showed that saffron supplementation sig-
nificantly reduced serum concentrations of TG and TC, and increased
serum HDL concentrations. However, it had no significant effect on
serum levels of FBS and LDL. However, saffron supplementation might
have beneficial effects on some plasma lipids, this was not clinically
significant. We suggest that higher doses of saffron and longer period of
intervention might make results clinically significant.
Hypercholesterolemia is one of the major risk factors for the develop-
ment of CVD. Hypolipidemic agents, including apolipoprotein B-100
antisense oligonucleotides, proprotein convertase subtilisin/kexin type
9 inhibitors, cholesteryl ester transfer protein inhibitors, and micro-
somal triglyceride transfer protein inhibitors are being used to control
dyslipidemia.27 There is a critical need to identity additional effective
hypolipidemic agents that can be used either in combination with sta-
tins, or alone, if statins are not tolerated.27 All of synthetic and natu-
rally-derived hypolipidemic compounds/therapies such as nu-
traceuticals represent alternative treatment strategies to decrease serum
cholesterol levels.27–30
Our analysis indicated that saffron supplementation significantly
reduced serum concentrations of TG and TC. Rare earlier studies have
investigated the effects of saffron or its constituents on serum levels of
these biomarkers. However, significant reductions in serum TG and TC
have been reported in animal studies.31 Saffron administration
(100mg/day) in patients with mild to moderate asthma reduced serum
concentrations of TG, as compared to placebo.32 However, intake of
saffron alcoholic extract (30mg/day) in patients with type 2 diabetes
mellitus did not affect serum levels of TG.14 Moreover, changes in
serum TG and TC in patients with metabolic syndrome were not sig-
nificant following intake of crocin (100mg/day).33 Administration of
crocin in patients with metabolic syndrome also did not change serum
concentrations of TC and TG.34 In the current meta-analysis, the si-
multaneous reduction of TG and increases of TC and HDL-C, without
any impact on LDL-C levels may be due to reduction of the cholesterol
content in non-HDL lipoproteins or even apoB. Further studies are
needed to confirm these findings.
Our meta-analysis also showed a significant increase in serum levels
of HDL following the administration of saffron. Treatment of diabetic
rats with saffron extract resulted in a significant increase in serum le-
vels of HDL.35 It also increased levels of HDL among diabetic en-
cephalopathy-induced rats.36 As same as for TG and TC, the effects of
saffron on serum levels of HDL has been investigated only in rare
human studies. Three months supplementation with saffron (30mg/
day) did not affect serum levels of HDL in patients with type 2 diabetes
mellitus.37 Administration of crocin in the same dosages for 8 weeks
also did not influence serum HDL concentrations in patients with me-
tabolic syndrome.34 Similar finding was also reached among patients
who were suffering from depression.38 Lack of adjustment for the
baseline values of HDL in that study might be as a cause for the non-
significant finding. Most patients with chronic diseases have impair-
ments in their serum levels of HDL at baseline.
We found no significant effects of saffron supplementation on serum
LDL and FPG concentrations. Intake of saffron supplements in patients
with metabolic syndrome did not change serum levels of fasting plasma
glucose.34 Saffron also had no significant effect on serum LDL con-
centrations among patients with depression.38 However, in a RCT on
patients with type 2 diabetes mellitus, three months supplementation
with saffron resulted in a significant reduction in serum levels of FPGTa
bl
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Figs. 2–6. Meta-analysis fasting blood glucose and lipid profile weighted mean difference estimates for 2) FBG, 3) TG, 4) TC, 5) LDL, 6) HDL, in the saffron and
placebo groups (CI= 95%).
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and LDL.39 In another study, saffron significantly reduced serum levels
of FPG in patients with metabolic syndrome.40 Most participants in
those studies were under treatment with common anti-diabetic and
anti-hyperlipidemia drugs, however, they did not perform any stratifi-
cation based on medicines used by the participants. Therefore, further
studies are needed to reach a firm conclusion.
Furthermore, a recently published meta-analysis in this regard did
not find a significant effect of saffron supplementation on lipid and
glucose profiles.20 However, they combined data from studies that used
either saffron or its active constituents. As reported in previous studies,
the specific bioactive components of saffron may have different meta-
bolic effects than saffron powder or its extracts.
Although the exact mechanisms through which saffron might in-
fluence serum levels of lipids are not clearly determined, the lipid-
modifying potency of saffron is attributed to its active constituents,
such as crocin. Crocin inhibits activity of pancreatic and gastric lipases
and recedes cholesterol and fat absorption.41 Lipases inhibition by
medications such as orlistat has demonstrated both TG and body weight
lowering effect.42 The possible TG-lowering effect of saffron may be
mediated by appetite suppressing and body weight reduction.43 More-
over, crocin can modulate lipid profile disorders through activation of
PPAR-α.44 A significant reduction in cholesteryl ester transfer protein
(CETP), one of the most important protein in the modulation of plasma
lipids profile and lipoproteins levels, following supplementation with
saffron has been reported previously.34 Inhibition of CETP will increase
serum concentrations of HDL-C.34 In addition, modulation of adipo-
nectin secretion, and antioxidant and anti-inflammatory properties of
saffron and its constituents are also among the other probable me-
chanisms for glucose and lipid-lowering effects of this herbal medi-
cine.45–48 Finally, saffron supplementation may also increase NO
bioavailability,49 the number of pancreatic beta cells, and insulin se-
cretion.50 Moreover, modulation of intracellular signaling pathways via
increases in AMPK phosphorylation is another potential mechanism in
this regard.51
The current meta-analysis is among the rare studies summarizing
findings from earlier studies on the effects of saffron supplementation,
Table 2
Subgroup analyses of saffron supplementation on glucose level and lipid profile.
NO WMD (95%CI) P within group P heterogeneity I2
Subgroup analyses of saffron supplementation on FBG level.
Baseline serum FBG (mg/dl)
< 100 2 −1.67 (-15.67, 12.33) 0.815 < 0.001 94.2%
>100 4 −7.84 (-22.71, 7.03) 0.301 0.004 77.7%
Trial duration (week)
<12 4 −6.59 (-22.04, 8.86) 0.403 < 0.001 86.6%
12 2 −4.82 (-15.70, 6.05) 0.385 0.116 59.4%
saffron dose (mg)
=30 4 −8.16 (-19.42, 3.10) 0.156 < 0.001 89.8%
>30 2 1.96 (-8.71, 12.63) 0.719 0.786 0.0%
Health condition
Non-type 2 diabetes 4 −1.42 (-10.63, 7.79) 0.763 < 0.001 83.9%
type 2 diabetes 2 −14.91 (-44.30, 14.48) 0.320 0.005 87.5%
Subgroup analyses of saffron supplementation on LDL level.
Baseline serum LDL (mg/dl)
< 100 3 −4.64 (-13.66, 4.38) 0.314 0.116 53.6%
>100 2 2.52 (-22.26, 27.30) 0.842 0.003 88.9%
Trial duration (week)
<12 3 2.19 (-10.55, 14.94) 0.735 0.010 78.1%
12 2 −9.56 (-22.81, 3.67) 0.157 0.166 47.8%
saffron dose (mg)
=30 3 0.02 (-14.26, 14.30) 0.998 0.005 81.3%
>30 2 −7.08 (-26.75, 12.59) 0.481 0.043 75.5%
Health condition
Non-type 2 diabetes 3 −8.39 (-15.19, -1.59) 0.016 0.359 2.5%
type 2 diabetes 2 7.63 (-5.70, 20.96) 0.262 0.052 73.5%
Subgroup analyses of saffron supplementation on HDL level.
Baseline serum HDL (mg/dl)
< 50 2 1.87 (-2.67, 6.41) 0.419 0.007 86.3%
>50 3 3.54 (0.87, 6.22) 0.009 0.218 34.4%
Trial duration (week)
<12 3 2.42 (-0.71, 5.55) 0.130 0.009 78.5%
12 2 3.28 (-2.05, 8.62) 0.228 0.081 67.1%
saffron dose (mg)
=30 3 4.37 (2.60, 6.13) <0.001 0.686 0.0%
>30 2 −0.22 (-2.08, 1.62) 0.810 0.752 0.0%
Health condition
Non-type 2 diabetes 3 3.54 (0.87, 6.22) 0.009 0.218 34.4%
type 2 diabetes 2 1.87 (-2.67, 6.41) 0.419 0.007 86.3%
Abbreviations: CI, confidence interval; FBG, fasting blood glucose; TG, triglycerides; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipo-
protein; WMD, weighted mean differences.
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but not its constituents, on serum lipid and glycemic profiles. However,
finding of current study should be interpreted with caution; because of
the following limitations. Firstly, the number of included studies for
each variable was limited. Moreover, due to the limited duration of
intervention in the included studies, we could not determine long-term
influence of saffron supplementation on lipid and glucose profiles. In
addition, most included studies were done in Iran, therefore, general-
ization of our findings to other nations should be done with caution.
Finally, high between-study heterogeneity is also another concern. We
tried to reduce this potential source of bias using different subgroup
analyses.
In conclusion, we found a significant reduction in serum con-
centrations of TC and TG following supplementation with saffron.
Saffron supplementation increased serum levels of HDL, but it had no
significant influence on serum FPG and LDL concentrations. Further
clinical trials with longer follow-up are needed.
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